Neoadjuvant radiation therapy concurrent with S-1 followed by systemic S-1/Gemcitabine therapy for Borderline resectable pancreatic cancer patients; A pilot study
Phase of Trial: Phase II
Latest Information Update: 12 May 2016
Price : $35 *
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 12 May 2016 Last checked against University Hospital Medical Information Network - Japan record.
- 15 Aug 2013 Status changed from recruiting to discontinued as reported by University Hospital Medical Information Network - Japan record.
- 18 Sep 2012 New trial record